1887
  1. Home
  2. Eurosurveillance
  3. Volume 25, Issue 22, 04/Jun/2020
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

The Canadian National Vaccine Safety (CANVAS) network monitors the safety of seasonal influenza vaccines in Canada.

Aim

To provide enhanced surveillance for seasonal influenza and pandemic influenza vaccines.

Methods

In 2017/18 and 2018/19 influenza seasons, adults (≥ 15 years of age) and parents of children vaccinated with the seasonal influenza vaccine participated in an observational study using web-based active surveillance. Participants completed an online survey for health events occurring in the first 7 days after vaccination. Participants who received the influenza vaccine in the previous season, but had not yet been vaccinated for the current season, were unvaccinated controls.

Results

In 2017/18, 43,751 participants and in 2018/19, 47,798 completed the online safety survey. In total, 957 of 30,173 participants vaccinated in 2017/18 (3.2%; 95% confidence interval (CI): 3.0–3.4) and 857 of 25,799 participants vaccinated in 2018/19 (3.3%; 95% CI: 3.1–3.5) reported a health problem of sufficient intensity to prevent their normal daily activities and/or cause them to seek medical care (including hospitalisation). This compared to 323 of 13,578 (2.4%; 95% CI: 2.1–2.6) and 544 of 21,999 (2.5%; 95% CI: 2.3–2.7) controls in each respective season. The event rate in vaccinated adults and children was higher than the background rate and was associated with specific influenza vaccines. The higher rate of events was associated with systemic symptoms and migraines/headaches.

Conclusion

In 2017/18 and 2018/19, higher rates of events were reported following seasonal influenza vaccination than in the pre-vaccination period. This signal was associated with several seasonal influenza vaccine products.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.22.1900470
2020-06-04
2024-11-17
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.22.1900470
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/22/eurosurv-25-22-5.html?itemId=/content/10.2807/1560-7917.ES.2020.25.22.1900470&mimeType=html&fmt=ahah

References

  1. Centers for Disease Control and Prevention (CDC). Impact of vaccines universally recommended for children--United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999;48(12):243-8. PMID: 10220251 
  2. Part 2 Vaccine Safety and Adverse Events Following Immunization. Canadian Immunization Guide. Evergreen Edition ed: Public Health Agency of Canada; 2012.
  3. World Health Organization (WHO). National Passive Surveillance. Geneva: WHO; 2019. [Accessed 23 Apr 2019]. Available from: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/en/
  4. IMPACT after 17 years: Lessons learned about successful networking. Paediatr Child Health. 2009;14(1):33-5.  https://doi.org/10.1093/pch/14.1.33  PMID: 19436462 
  5. Scheifele DW, Halperin SA, CPS/Health Canada, Immunization Monitoring Program, Active (IMPACT). Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis. 2003;14(3):213-9.  https://doi.org/10.1016/S1045-1870(03)00036-0  PMID: 12913834 
  6. Lapphra K, Dobson S, Bettinger JA. Acceptability of Internet adverse event self-reporting for pandemic and seasonal influenza immunization among health care workers. Vaccine. 2010;28(38):6199-202.  https://doi.org/10.1016/j.vaccine.2010.07.019  PMID: 20654668 
  7. Newes-Adeyi G, Greece J, Bozeman S, Walker DK, Lewis F, Gidudu J. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system. Vaccine. 2012;30(6):1050-5.  https://doi.org/10.1016/j.vaccine.2011.12.041  PMID: 22200501 
  8. Härmark L, van Hunsel F, Hak E, van Grootheest K. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring. Vaccine. 2011;29(10):1941-7.  https://doi.org/10.1016/j.vaccine.2010.12.123  PMID: 21236235 
  9. Bettinger JA, Rouleau I, Gariepy MC, Bowie WR, Valiquette L, Vanderkooi OG, et al. . Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012. Euro Surveill. 2015;20(29):21189.  https://doi.org/10.2807/1560-7917.ES2015.20.29.21189  PMID: 26227369 
  10. De Serres G, Gariépy MC, Coleman B, Rouleau I, McNeil S, Benoît M, et al. , PHAC-CIHR influenza Research Network (PCIRN). Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine. PLoS One. 2012;7(7):e38563.  https://doi.org/10.1371/journal.pone.0038563  PMID: 22802929 
  11. Pillsbury A, Quinn H, Cashman P, Leeb A, Macartney K, AusVaxSafety consortium. Active SMS-based influenza vaccine safety surveillance in Australian children. Vaccine. 2017;35(51):7101-6.  https://doi.org/10.1016/j.vaccine.2017.10.091  PMID: 29128379 
  12. Bettinger JA, Vanderkooi OG, MacDonald J, Kellner JD. Rapid online identification of adverse events after influenza immunization in children by PCIRN’s National Ambulatory Network. Pediatr Infect Dis J. 2014;33(10):1060-4.; Rapid online.  https://doi.org/10.1097/INF.0000000000000373  PMID: 25361187 
  13. Halsey NA, Talaat KR, Greenbaum A, Mensah E, Dudley MZ, Proveaux T, et al. The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. Vaccine. 2015;33(Suppl 5):F1-67.  https://doi.org/10.1016/j.vaccine.2015.10.080  PMID: 26822822 
  14. Cashman P, Moberley S, Dalton C, Stephenson J, Elvidge E, Butler M, et al. Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children. Vaccine. 2014;32(42):5503-8.  https://doi.org/10.1016/j.vaccine.2014.07.061  PMID: 25077424 
  15. Cashman P, Macartney K, Khandaker G, King C, Gold M, Durrheim DN. Participant-centred active surveillance of adverse events following immunisation: a narrative review. Int Health. 2017;9(3):164-76.  https://doi.org/10.1093/inthealth/ihx019  PMID: 28582563 
  16. Pillsbury AJ, Glover C, Jacoby P, Quinn HE, Fathima P, Cashman P, et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018;8(10):e023263.  https://doi.org/10.1136/bmjopen-2018-023263  PMID: 30341132 
  17. Pillsbury A, Cashman P, Leeb A, Regan A, Westphal D, Snelling T, et al. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015. Euro Surveill. 2015;20(43):30050.  https://doi.org/10.2807/1560-7917.ES.2015.20.43.30050  PMID: 26536867 
  18. Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB, et al. How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. J Occup Environ Med. 2009;51(7):786-96.  https://doi.org/10.1097/JOM.0b013e3181a86671  PMID: 19528832 
  19. Clothier HJ, Selvaraj G, Easton ML, Lewis G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10(12):3726-30.  https://doi.org/10.4161/hv.34369  PMID: 25483686 
  20. Lindemann N. What's the average survey response rate [2019 benchmark]. SurveyAnyplace Blog; 2019. [Accessed 10 Feb 2020]. Available from: https://surveyanyplace.com/average-survey-response-rate/
  21. Post-approval safety data management: definitions and standards for expedited reporting. E2D. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2003. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf
  22. De Serres G, Billard M, Gariépy M, Rouleau I, Toth E, Landry M. Rapport final de surveillance de la sécurité de la vaccination des jeunes de 20 ans et moins contre le méningocoque de sérogroupe B au Saguenay–Lac-Saint-Jean. [Final report on surveillance of vaccination safety in young people aged 20 and under against serogroup B meningococcus in Saguenay – Lac-Saint-Jean]. Quebec City: Institut National de Santé Publique du Québec; 2016.
2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Julie+A+Bettinger&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bettinger Julie A</a>, <a href="/search?value1=Gaston+De+Serres&option1=author&noRedirect=true" class="nonDisambigAuthorLink">De Serres Gaston</a>, <a href="/search?value1=Louis+Valiquette&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Valiquette Louis</a>, <a href="/search?value1=Otto+G+Vanderkooi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vanderkooi Otto G</a>, <a href="/search?value1=James+D+Kellner&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kellner James D</a>, <a href="/search?value1=Brenda+L+Coleman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Coleman Brenda L</a>, <a href="/search?value1=Karina+A+Top&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Top Karina A</a>, <a href="/search?value1=Jennifer+E+Isenor&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Isenor Jennifer E</a>, <a href="/search?value1=Anne+E+McCarthy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">McCarthy Anne E</a>, <a href="/search?value1=on+behalf+of+the+Canadian+Immunization+Research+Network&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Canadian Immunization Research Network</a></span>. 2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network. <a href="/content/ecdc">Euro Surveill.</a> 2020;25(22):pii=1900470. <a href="https://doi.org/10.2807/1560-7917.ES.2020.25.22.1900470" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2020.25.22.1900470</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 12 Jul 2019;&nbsp;&nbsp; <span class="generated">Accepted</span>: 20 Mar 2020 </span> </p>
/content/10.2807/1560-7917.ES.2020.25.22.1900470
/content/10.2807/1560-7917.ES.2020.25.22.1900470
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error